Suggested remit - To appraise the clinical and cost effectiveness of Pembrolizumab within its marketing authorisation for treating untreated, locally advanced or metastatic, triple negative breast cancer
Status In progress
Process STA 2018
ID number 1546

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
10 June 2019 - 08 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance